Real-world check: does acalabrutinib deliver for CLL patients in belarus?
NCT ID NCT07288515
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tracks 50 adults with chronic lymphocytic leukemia (CLL) who are starting acalabrutinib alone (no other cancer drugs). Researchers will watch how long patients stay on the drug and why they might stop, aiming to fill a gap in real-world data. No new treatment is tested; it simply observes routine care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGMinsk, Belarus
Conditions
Explore the condition pages connected to this study.